share_log

Illumina | 8-K: Current report

Illumina | 8-K: Current report

Illumina | 8-K:重大事件
美股SEC公告 ·  06/04 05:27

牛牛AI助理已提取核心訊息

Illumina, Inc., a biotechnology company, has announced the approval of a Spin-Off of its subsidiary GRAIL, LLC by its board of directors. The Spin-Off will result in the distribution of at least 85.5% of GRAIL's common stock to Illumina's shareholders as a pro rata dividend. This distribution is scheduled to be effective on June 24, 2024, at 12:01 AM New York City time, with GRAIL expected to commence trading on the Nasdaq Global Select Market under the ticker symbol 'GRAL' the following day. Shareholders of Illumina as of the record date, June 13, 2024, will receive one share of GRAIL for every six shares of Illumina they own. The Spin-Off is contingent upon certain conditions outlined in GRAIL's Form 10 registration...Show More
Illumina, Inc., a biotechnology company, has announced the approval of a Spin-Off of its subsidiary GRAIL, LLC by its board of directors. The Spin-Off will result in the distribution of at least 85.5% of GRAIL's common stock to Illumina's shareholders as a pro rata dividend. This distribution is scheduled to be effective on June 24, 2024, at 12:01 AM New York City time, with GRAIL expected to commence trading on the Nasdaq Global Select Market under the ticker symbol 'GRAL' the following day. Shareholders of Illumina as of the record date, June 13, 2024, will receive one share of GRAIL for every six shares of Illumina they own. The Spin-Off is contingent upon certain conditions outlined in GRAIL's Form 10 registration statement with the SEC. In conjunction with the Spin-Off, Illumina anticipates incurring charges between $35 and $50 million, mainly for legal and advisory fees, with the majority expected in Q2 and the remainder by Q3 of 2024. Additionally, the Spin-Off may lead to a potential goodwill impairment for Illumina, which could be recognized following an interim test in Q2 of 2024. The company's balance sheet as of March 31, 2024, shows $1,466 million in goodwill, $561 million in non-amortizing in-process research and development, and $2,092 million in net amortizing intangible assets related to GRAIL.
生物技術公司illumina宣佈經由董事會批准子公司GRAIL,LLC的分拆。這次分拆將至少將GRAIL公共股票的85.5%作為比例分配股息派發給illumina的股東。此次分配將於2024年6月24日(美國紐約時間)早上12:01生效,GRAIL預計在隔日(Nasdaq開盤日)以'GRAL'的標的在Nasdaq Global Select Market上掛牌交易。在截至2024年6月13日的股權登記日前,即使持有六股illumina也僅將獲得一股GRAIL。分拆取決於GRAIL提交給SEC的Form 10登記申明書中所述的某些條件。與此同時,illumina預計將因法律和顧問費用而承擔350...展開全部
生物技術公司illumina宣佈經由董事會批准子公司GRAIL,LLC的分拆。這次分拆將至少將GRAIL公共股票的85.5%作為比例分配股息派發給illumina的股東。此次分配將於2024年6月24日(美國紐約時間)早上12:01生效,GRAIL預計在隔日(Nasdaq開盤日)以'GRAL'的標的在Nasdaq Global Select Market上掛牌交易。在截至2024年6月13日的股權登記日前,即使持有六股illumina也僅將獲得一股GRAIL。分拆取決於GRAIL提交給SEC的Form 10登記申明書中所述的某些條件。與此同時,illumina預計將因法律和顧問費用而承擔3500萬至5億美元的費用,其中大部分預計將在2024年第二季度支付,其餘部分預計在2024年第三季度支付。另外,分拆可能會導致illumina的商譽減損,此問題可能會在2024年第二季度的中期檢測後得到認定。截至2024年3月31日,該公司資產負債表顯示商譽額度為14.66億美元,不計攤銷的研發經費達5.61億美元,與GRAIL相關的淨攤銷無形資產為20.92億美元。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。